Are you Dr. Ganz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 79 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1001 Potrero Ave
San Francisco General Hospital 5G1
San Francisco, CA 94110Phone+1 415-206-3024Fax+1 415-206-5447
Summary
- Dr. Peter Ganz, MD is a cardiologist in San Francisco, California. He is currently licensed to practice medicine in California and Massachusetts. He is affiliated with Zuckerberg San Francisco General Hospital and Trauma Center and is a Professor at University of California.
Education & Training
- Brigham and Women's HospitalFellowship, Cardiovascular Disease, 1979 - 1981
- Massachusetts General HospitalResidency, Internal Medicine, 1976 - 1979
- Harvard Medical SchoolClass of 1976
Certifications & Licensure
- CA State Medical License 2007 - 2025
- MA State Medical License 1978 - 2009
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- The Contribution of Endothelin to Vasomotor Function in Diseased Coronary Arteries Start of enrollment: 1998 Nov 01
- Imaging of Plaque With Magnetic Resonance Imaging (MRI) Start of enrollment: 2001 Jan 01
- Atherosclerosis in Rheumatoid Arthritis Start of enrollment: 2009 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 59 citationsComparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.Ron Rawlings, Anju Nohria, Ping Yen Liu, Jason Donnelly, Mark A. Creager
The American Journal of Cardiology. 2009-02-15 - 1696 citationsEffect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis A Randomized Controlled TrialSteven E. Nissen, E. Murat Tuzcu, Paul Schoenhagen, B. Greg Brown, Peter Ganz
JAMA. 2004-03-03 - 314 citationsEffect of ACAT inhibition on the progression of coronary atherosclerosis.Steven E. Nissen, E. Murat Tuzcu, H. Bryan Brewer, Ilke Sipahi, Stephen J. Nicholls
The New England Journal of Medicine. 2006-03-23
Press Mentions
- Prevention of Cardiovascular Diseases and Dementia: The Emerging Role of Air Pollution, Socioeconomic Factors, E-cigarettes, New Biomarkers, Proteomics, and GeneticsNovember 17th, 2020
- A "Liquid Health Check" Could Help Predict Disease RiskDecember 4th, 2019
- Blood-Based “Liquid Health Check” Beats Traditional Predictors of Multiple Disease RisksDecember 3rd, 2019
- Join now to see all
Professional Memberships
- Member